We recently characterized a heparin-deficient mouse strain generated by targeting the gene for N-deacetylase/N-sulfotransferase-2 (NDST-2). The NDST-2 -/-mice show severe defects in their organization of mast cell (MC) secretory granules, with an almost total absence of the various heparin-binding MC proteases. In the present report we have studied the consequences of heparin/MC protease deficiency for extravascular coagulation and fibrinolysis. Addition of prothrombin to peritoneal cells-a mixture of macrophages, lymphocytes, and MCs-resulted in formation of thrombin but the accumulation of thrombin occurred faster in the NDST-2 -/-cells than in normal controls. Further, the generated thrombin was subsequently inactivated in the NDST-2 +/+ cell cultures but not in the NDST-2 -/-cells. Plasminogen was activated to plasmin at an apparently higher rate in peritoneal cells from NDST-2 null mice than in the normal controls. Similar to thrombin, the generated plasmin was inactivated by NDST-2 +/+ but not by the NDST-2 -/-cells. Subsequent experiments with normal cells showed that cell surface-associated MC chymase, in a strongly heparin-dependent manner, was responsible for both the thrombininactivating-and plasmin-inactivating activities. These results show that MC chymase-heparin complexes have the potential to regulate extravascular coagulation processes, as well as the plasminogen activator/plasmin system. Key words: heparin proteoglycan • plasmin • thrombin M ast cells (MCs) are key effector cells in various types of inflammatory reactions, most notably allergic reactions. They have also been implicated in several other pathophysiological conditions, such as rheumatoid arthritis (1), tumor metastasis (2), and wound healing (3). MCs can be activated by different mechanisms; for example, crosslinking of surface-bound IgE molecules, and in this process they release the contents of their secretory granules. The MC granules contain several preformed inflammatory mediators, including histamine, heparin proteoglycan (PG), cytokines, and various proteases. In addition, the MCs perform de novo synthesis of other classes of inflammatory mediators following activation; for example, LTC 4 and PGD 2 (4).
The exact biological function(s) of the MC proteases has not been outlined. Several studies have indicated potent pro-inflammatory activities of both tryptases as well as chymases when these proteases have been injected either peritoneally or into the skin, or when inhaled into the lungs (9, (17) (18) (19) (20) (21) (22) . However, the actual in vivo target proteins or peptides for the MC proteases during these processes have not been identified. Previous studies have identified a variety of potential substrates for different MC proteases in vitro. Generally, the tryptases prefer low-molecularweight peptides as substrates (23) , whereas the chymases are known to degrade a variety of macromolecular substrates. Although the nature of the various potential substrates for MCproteases is variable, indicating potential involvement of the MC proteases in a variety of biological process, it is noteworthy that several of the known MC protease substrates belong to the coagulation system (24) (25) (26) . This may indicate a role for MC proteases in the regulation of the extravascular coagulation processes that are usually associated with inflammation. Therefore, the aim of the present study was to assess possible effects of the lack of heparin and heparindependent MC proteases on the regulation of extravascular coagulation, as well as on the associated plasminogen activation/plasmin system. To this end, peritoneal cells, a cell population containing macrophages and lymphocytes, as well as MCs, were chosen. Our results demonstrate that MC chymase in collaboration with heparin PG may have a biological role in the regulation of thrombin and plasmin.
MATERIALS AND METHODS

Reagents
The chromogenic peptide substrates S-2586, S-2403, S-2238, and S-2222 were from Chromogenix (Mölndal, Sweden). Purified human prothrombin, rabbit anti-human prothrombin serum, and rabbit anti-human plasminogen serum were purchased from Diagnostica STAGO (Asnieres, France). Bovine α-thrombin was donated by Ingemar Björk (Swedish University of Agricultural Sciences, Dept. of Veterinary Medical Chemistry, Uppsala, Sweden). Plasminogen (Glu-Type), α 1 -antichymotrypsin and calcium ionophore A23187 were purchased from Calbiochem (La Jolla, CA). Plasmin was purchased from either Sigma or Calbiochem (La Jolla, CA). Plasminogen activator inhibitor 1 (PAI-1) was from Calbiochem-Novabiochem (Bad Soden, Germany). Protamine (M r ~ 4500) grade IV, bacterial lipopolysaccharide (LPS) from E. coli, type 055:B5, and amiloride were obtained from Sigma (St. Louis, MO). Rabbit anti-rodent urokinase plasminogen activator (uPA) IgG was from American Diagnostica Inc. (Greenwich, CT). Control rabbit IgG was obtained from pre-immune rabbit serum by affinity chromatography on Protein A Sepharose (Amersham Pharmacia Biotech, Uppsala, Sweden). Purified anti-mouse IgE (R35-72) was from PharMingen (San Diego, CA), and donkey anti-rabbit Ig conjugated to horseradish peroxidase was purchased from Amersham Pharmacia Biotech. Bovine Factor X was a gift from by Johan Stenflo (Department of Clinical Chemistry, Malmö General Hospital, Malmö, Sweden).
Cells
Peritoneal cells from NDST-2 +/+ mice and corresponding NDST-2 -/-mice (females, 12-15 weeks old) were collected by peritoneal washing with 10 ml of cold phosphate-buffered saline (PBS), pH 7.4. We note that cell surface-associated chymase activities are increased with increased age of the mice. Cells were centrifuged (300 x g, 4°C, 10 min) and were cultured in serum-free medium QBSF 51 (Sigma). The serum-free medium was supplemented with penicillinstreptomycin (100 IU/ml, 100 mg/ml; Life Technologies, Inc., Rockville, MD). The cells were distributed in 24-well plates (Nunc; ~ 0.5×10 6 cells in 0.4 ml/well). Cells were incubated at 37°C in a humidified atmosphere of 5% CO 2 .
Enzymatic assays
Assays for thrombin-generating activity and thrombin-inactivating activity, as well as plasmingenerating activity and plasmin-inactivating activity, were generally performed after overnight incubation of cells. Prothrombin (2 µg/well), thrombin (1 µg/well), plasminogen (2 µg/well), plasmin (2 µg/well) or Factor X (2 µg/well) were added to the cell cultures in duplicates and samples (50 µl) from spent media were collected at various time points and frozen at -20°C. Activation of Factor X was measured on cells that had been incubated overnight with or without LPS (1 µg/well). Aliquots (20 µl) of the samples were transferred to 96-well microtiter plates and mixed with 200 µl of PBS. Activity levels for the different proteases were subsequently assayed by using different chromogenic substrates. Thrombin activity was assayed with S-2238 (20 µl added from a 4.6 mM solution in H 2 O); plasmin was assayed with S-2403 (20 µl added from a 3 mM solution in H 2 O); Factor X was assayed with S-2222 (20 µl added from a 1.4 mM solution in H 2 O). Initial rates of substrate hydrolysis were monitored at 405 nm with a Titertek Multiskan Spectrophotometer (MTX Lab Systems, Vienna, VA). The effect of protamine and α 1 -antichymotrypsin on the various processes was studied by first adding these substances, incubating 30 min, followed by addition of protease or zymogen and further analysis as above.
Identification of the type of plasminogen activator was studied by adding specific inhibitors to NDST-2 +/+ cells that had been incubated overnight: PAI-1 (9 µg/well), rabbit anti-rodent uPA IgG (20 µg/well), control rabbit IgG (20 µg/well), amiloride (0.01 mM, 0.1 mM, 1 mM; amiloride was diluted from a 100 mM stock solution in dimetyl sulphoxide). After further incubation (~ 30 min), plasminogen (2 µg/well) was added to cell cultures. Generated plasmin was monitored as above. To study the effect of MC activators on plasmin processing, purified anti-mouse IgE (2 µg/well) or calcium ionophore A23187 (0.5 µM) were added to overnight NDST-2 +/+ cell cultures, followed by further incubation of the cells for ~30 min. Plasmin (2 µg/well) was added to cell cultures, followed by collection of samples and measurement of plasmin activity as described above. For direct measurements of chymase activities, NDST-2 +/+ peritoneal cells were added to 96-well microtiter plates (~1×10 5 cells in 0.2 ml PBS/ well).
Protamine (0.1 µg, 1 µg, 10 µg/well) or calcium ionophore A23187 (0.2 µM, 0.5 µM) were added. After 30 min, the plates were centrifuged (300 x g, 4°C, 10 min), followed by transfer of cell supernatants into new wells and addition of new PBS to cell-containing wells. Chymase activity was measured after addition of 20 µl of a solution (1.8 mM in H 2 O) of the chromogenic substrate S-2586.
Western blot analysis
We added prothrombin (2 µg/well) or plasminogen (2 µg/well) to NDST-2 +/+ and NDST-2 -/-peritoneal cell cultures. Samples (300 µl) from conditioned media were taken after various time points and were mixed with 3× sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer. Samples (40 µl) of these mixtures were subjected to SDS-PAGE on 12% polyacrylamide gels under nonreducing conditions in a Laemmli system. Proteins were subsequently blotted onto nitrocellulose membranes, followed by blocking with 5% milk powder in PBS for 2 h, 20°C. Next, the membranes were incubated with rabbit anti-human prothrombin or rabbit anti-human plasminogen, diluted (1:100) in 5% milk powder/PBS/0.1% Tween 20, at 4°C for 20 h. After the membranes were washed extensively with TBS/ 0.1% Tween 20, they were incubated with donkey anti-rabbit Ig conjugated to horseradish peroxidase (Amersham, Life Science; 1: 3000 dilution in TBS/0.1% Tween 20). After 45 min of incubation (20°C), the membranes were washed extensively with TBS/0.1% Tween 20, followed by washing with TBS without detergent. The membranes were developed with the enhanced chemiluminescence system system (Amersham Pharmacia Biotech, Uppsala, Sweden) according to the protocol provided by the manufacturer.
Purification of MCs
We collected peritoneal cells from normal mice (females, 12-15 weeks old) by peritoneal washing with 10 ml of cold PBS, pH 7.4. MCs (connective tissue type) of ~95% purity (the majority of the contaminating cells were red blood cells), as judged by staining with toluidine blue, were prepared by density gradient centrifugation on metrizamide (27) . Cells from the interphase between the PBS and metrizamide contained peritoneal cells depleted from MCs. These cells were recovered, centrifuged (300 x g, 5 min), resuspended in PBS, centrifuged again and resuspended in cell culture medium before further use.
RESULTS
Previous studies have shown that peritoneal macrophages express potent prothrombinase activity (28, 29) . In this study, the NDST-2 -/-mice were used as a model for studying the biological consequences of heparin deficiency for the macrophage prothrombinase.
Total peritoneal cell populations were cultured from both NDST-2 +/+ and NDST-2 -/-mice.
Addition of prothrombin to the peritoneal cells resulted in rapid formation of thrombin (Fig. 1) . Thrombin accumulation was considerably faster in the NDST-2 -/-cells than in normal controls.
Further, the generated thrombin was subsequently inactivated in the NDST-2 +/+ cell cultures but not in the NDST-2 -/-cells (Fig. 1A) . No thrombin generation was observed when cells were cultured in the absence of added prothrombin or when prothrombin was incubated without cells (results not shown). These results thus indicate that regulation of thrombin activity in the peritoneal cell system is strongly heparin-dependent. To study the role of heparin in thrombin regulation further, we used protamine, a polycationic heparin antagonist, that will bind strongly to heparin. Addition of protamine to NDST-2 +/+ cell cultures resulted in acceleration of the accumulation of thrombin and it abolished subsequent thrombin inactivation (Fig. 1A) , further supporting a role for heparin PG in thrombin regulation.
Earlier studies have shown that thrombin is a substrate for MC chymase (24, 30) . Because the NDST-2 -/-peritoneal MCs are essentially completely devoid of MC chymase at the protein level, it appeared likely that chymase is the enzyme responsible for thrombin regulation in the peritoneal cell population. Indeed, addition of the chymase inhibitor α 1 -antichymotrypsin to wild-type cells resulted in a marked increase in the rate of thrombin formation, as well as in decreased subsequent thrombin inactivation ( The processing of prothrombin in the peritoneal cell cultures was studied further by immunoblot analysis by using an anti-prothrombin antiserum. After addition of prothrombin to both NDST-2 +/+ and NDST-2 -/-cells, we observed rapid formation of thrombin (Fig. 1C) . In NDST-2 +/+ cell cultures, the band corresponding to generated thrombin was reduced over time, consistent with degradation into fragments that were not detected by the anti-prothrombin antibody. In contrast, the thrombin band was accumulated in samples from NDST-2 -/-cell cultures and was still present even after 20 h, in agreement with reduced rate of chymase-catalyzed inactivation. Intact ~38 kDa thrombin was converted into a ~37 kDa band in NDST-2 -/-cultures (see 20 h sample).
Earlier studies showed that rat chymase can convert intact 38 kDa thrombin to a 37 kDa fragment without loss of catalytic activity (31) . Possibly, the small amounts of chymase still present in the NDST-2 -/-cell cultures (6) are sufficient to cause this conversion but not further degradation during the time period studied.
Previous studies have shown that peritoneal macrophages can activate Factor X to Factor Xa (29) . To assess whether heparin PG influences the activation of Factor X, purified Factor X was added to the NDST-2 +/+ and NDST-2 -/-cell cultures. Before Factor X addition, the cells had been incubated ~20 h with or without LPS. LPS is a known stimulus for tissue factor expression and hence for Factor X activation (32) . Media samples were collected at various time points, followed by measuring of generated Factor Xa-like activity. Results displayed in Figure 2 show that LPS causes stimulation of Factor X-activating activities in both NDST-2 +/+ and NDST-2 -/-cell cultures. However, Factor X activation was similar in peritoneal cell populations from both NDST-2 +/+ and NDST-2 -/-mice ( Fig. 2 ), indicating that heparin PG does not affect LPS signaling and that heparin PG is not important for the regulation of extravascular Factor X activation.
The NDST-2 -/-mice were also used as a model to study the possible influence of heparin PG on the extravascular plasmin/plasminogen activator system. Addition of plasminogen to peritoneal cell populations from NDST-2 +/+ and NDST-2 -/-mice resulted in generation of an enzyme that cleaved the chromogenic plasmin substrate S-2403, indicating plasmin formation. No S-2403 hydrolyzing activity was formed in the absence of added plasminogen or if plasminogen was incubated without cells (results not shown). Plasmin was formed at a higher rate in peritoneal cells from NDST-2 -/-mice than in the normal controls (Fig. 3A) . Similar to thrombin (see above), the generated plasmin was subsequently inactivated in NDST-2 +/+ but not NDST-2 -/-cell cultures. Analogous experiments with plasmin added to cell cultures showed marked plasmin inactivation in the NDST-2 +/+ cell cultures but not in the NDST-2 -/-cells (Fig. 3B) . Subsequent experiments showed that both protamine and α 1 -antichymotrypsin caused accelerated plasmin accumulation after addition of plasminogen (Fig. 3A) and essentially complete inhibition of plasmin inactivation (Fig. 3A-B ). This finding indicates that heparin PG and chymase take part in plasmin regulation. Addition of protamine or α 1 -antichymotrypsin to NDST-2 -/-cells did not affect their activities towards plasminogen or plasmin (results not shown).
Plasminogen processing was investigated further by immunoblot analysis using an antiserum to plasminogen. Plasminogen was converted to lower molecular weight compounds both in NDST-2 +/+ and NDST-2 -/-cell cultures (Fig. 3C ). Whereas these compounds appeared to be degraded further in the NDST-2 +/+ cells, however, accumulation of 30-50 kDa bands was observed in NDST-2 -/-cell cultures. These results are thus consistent with plasminogen activation in both NDST-2 +/+ and NDST-2 -/-cells, but with further inactivating chymase-catalyzed cleavages occurring mainly in NDST-2 +/+ cultures.
To establish the importance of MC products for plasmin regulation further, we performed experiments with peritoneal cells that had been depleted of MCs. The results displayed in Figure  4 show that reconstitution of MC-depleted peritoneal cells with purified MCs resulted in decreased accumulation of plasmin after addition of plasminogen (Fig. 4A) , as well as markedly increased plasmin inactivation (Fig. 4B ).
The mechanism responsible for the generation of plasmin in the peritoneal cell cultures was investigated. Addition of PAI-1 to cell cultures before addition of plasminogen resulted in considerable inhibition of plasmin-generating activity, indicating that plasminogen activator was responsible for formation of plasmin (Fig. 9A) . Plasminogen activators may be of either the tissue type (tPA) or the urokinase type (uPA). To determine the type of plasminogen activator, cell cultures were incubated with antibodies towards uPA, followed by addition of plasminogen and measurement of plasmin generation. The anti-uPA antibodies produced significant inhibition of the plasminogen activator, indicating that uPA is involved in plasminogen activation. In contrast, control antibodies had no detectable inhibitory effect on plasmin gereration (Fig. 5A ).
Amiloride produced dose-dependent inhibition of the plasminogen activator with complete inhibition achieved at 1 mM. Amiloride has been shown previously to inhibit uPA but not tPA (33) , thus giving further support for uPA as the major plasminogen activator in the peritoneal cell system (Fig. 5B ). Macrophages are known to adhere to plastic surfaces, whereas lymphocytes do not adhere. After separation of the peritoneal cells into adherent and nonadherent populations, it was observed that plasminogen activation was seen mainly in cultures of adherent cells, indicating that uPA is expressed by macrophages rather than lymphocytes (results not shown).
The effect of MC activation on plasmin regulation was studied. It is known that stimulation of MCs with calcium ionophore and anti-IgE induces MC degranulation with release of the secretory granule contents. Addition of calcium ionophore A23187 or anti-IgE antibody to NDST-2 +/+ peritoneal cells resulted in increased rates of plasmin inactivation, indicating that MC activation causes release of heparin PG and chymase with increased plasmin inactivation as a result (Fig. 6 ). However, because calcium ionophore may induce secretion by cell types other than MCs present in the peritoneal population, we cannot rule out that the increased plasmin inactivation observed after A23187 addition may involve mechanisms other than MC degranulation. We performed analogous experiments by adding plasminogen to activated MCs. In cell cultures with anti-IgE-activated MCs, plasmin was accumulated at a reduced rate compared with controls with nonactivated MCs in agreement with the findings above (results not shown).
Experiments were conducted to investigate further how protamine affects the chymase-heparin PG complexes. The studies described above indicate that chymase-catalyzed degradation of thrombin and plasmin is inhibited in the presence of protamine. However, the results do not discriminate between direct effects of protamine on the chymase active site or whether protamine acts by blocking thrombin-and plasmin-binding sites on the chymase-associated heparin PG. To test these alternatives, the effect of protamine on chymase-catalyzed cleavage of a chromogenic peptide substrate, S-2586, was tested. Because the cleavage of S-2586 is affected only partly by heparin (34), protamine should not cause a major effect on the cleavage of this substrate, provided that its effect is directed mainly toward the heparin moiety of the chymase-heparin PG complex. Moreover, we wanted to investigate whether protamine can cause release of free chymase molecules from the chymase-heparin PG complexes into the medium. To this end, protamine at different concentrations was added to peritoneal cells present in 96-well microtiter plates. Subsequently, the plates were centrifuged and the cell supernatants were transferred to new wells (medium fraction). Fresh buffer was added to wells containing cells (cell fraction). Next, chymase activities in the cell and medium fractions were assayed by adding S-2586. The results in Figure 7 show that most of the chymase activity is cell-associated, both before and after protamine addition. Thus, protamine does not cause any major release of chymase activity from the cells into the medium. Moreover, protamine has only a slight direct inhibitory effect on cell surface-associated chymase activity toward S-2586, in agreement with the notion that protamine does not affect the actual active site of chymase but rather interacts with the adjacent heparin glycosaminoglycan.
The results presented here, as well as in earlier observations, have shown that chymase-heparin PG complexes are found on the cell surface on unstimulated MCs (24, 35) . Further experiments were conducted to investigate the location of chymase/heparin PG complexes after MC activation. Before MC activation, the majority of the chymase activity was present on the cell surface (Fig. 8) . Activation of cells with A23187 resulted in increased chymase activity on the cell surface, as well as in release of chymase activity into the medium. Even after MC activation, however, most of the chymase activity was on the cell surface (Fig. 8 ).
DISCUSSION
MCs synthesize enormous amounts of proteases, which are stored within their secretory granules. As much as 25% of the total cell protein in a MC can be constituted by various proteases (35) . Consequently, when MCs degranulate, vast amounts of these powerful enzymes escape into the tissue and have the potential to influence various biological processes at sites where MCs are present. Because MCs are known to be involved in various different diseases (see first section after abstract), the MC proteases may thus have the potential to regulate such conditions at many different levels. The elucidation of the true in vivo function(s) of the MC proteases has not been achieved yet and may indeed be a complex issue, given the wide array of pathological conditions in which MCs participate. Ultimately, defining the biological function of these enzymes involves identification of their physiological substrates in vivo. However, most likely the substrates for these enzymes may vary depending on the environment present during their release, which in turn reflects the particular prevalent pathological condition.
The recent development of a mouse strain deficient in heparin has provided an invaluable tool for studying the function of MC proteases. In mouse, MCs are divided into two subclasses, mucosal and connective tissue MCs. It is only the connective tissue subtype that synthesizes heparin; the mucosal MCs instead synthesize the related polysaccharide chondroitin sulfate (36) . The mucosal-and connective tissue type MCs show highly different expression patterns regarding proteases, where the mucosal subtype expresses the chymases mouse MC protease 1 (mMCP-1)(37) and mMCP-2 (38), whereas the connective tissue subclass expresses the chymases mMCP-4 (37, 39) and mMCP-5 (37, 40) and the tryptases mMCP-6 (41) and mMCP-7 (42), as well as carboxypeptidase A (43) . The connective tissue MC proteases are generally tightly associated with heparin PG during storage and are released in complex with heparin during degranulation. Because the targeting of NDST-2 affects only heparin but not chondroitin sulfate synthesis, the NDST-2 inactivation will thus only affect the connective tissue type of MCs. Hence, the NDST-2 -/-mice will aid in understanding the biology of connective tissue-type MC proteases but not of the mucosal MC counterparts. A recent report showed that inactivation of the gene for one of the mucosal MC proteases, mMCP-1, impaired the ability of these mice to combat infection by Trichinella spiralis (44) .
In this report, we demonstrate that the inactivation of NDST-2, and thus of the heparin/MC protease system, may affect the regulation of coagulation at extravascular sites, as exemplified by the peritoneal cavity. Previous studies have shown that extravascular activation of the coagulation system, accompanied by extravascular fibrin deposition, is a consistent feature of various inflammatory reactions; for example, delayed-type hypersensitivity reactions (45, 46) . The function of these extravascular fibrin deposits is not clear, but may involve trapping of invading antigens/microbes at the inflammatory site or restriction of the movement of inflammatory cells within the tissue. Macrophages are thought to be the main cell type responsible for initiation of coagulation under such circumstances by expressing various coagulation factors, including tissue factor, Factor VII, Factor X, and Factor V. We have shown previously that peritoneal macrophages can assemble these coagulation factors into active Factor X-activating and prothrombinase complexes (29, 47) . In this report, we show that MC chymaseheparin PG complexes may modulate such extravascular coagulation at the level of inactivating thrombin, by cleaving this protease into inactive fragments. In contrast, Factor Xa did not seem to be affected by the chymase-heparin complexes. No significant levels of serpin protease inhibitors, capable of inhibiting thrombin, appear to be produced within this cellular system. If this class of protease inhibitors; for example, antithrombin, protease nexins, or heparin cofactor II, contributed to the observed thrombin regulation, we would find a resulting formation of higher molecular covalent serpin-thrombin complexes that would be detected on SDS-PAGE analysis. Moreover, we would not expect that the expression of serpins (by macrophages, for example) would be affected by the NDST-2 knockout. Because no inhibition of thrombin was detected in NDST-2 -/-cells cultures and no serpin-thrombin complexes were observed, we therefore conclude that the chymase-heparin complexes constitute the major regulatory mechanism for thrombin in this cellular system.
Our results thus open the possibility that MCs may have a role in the regulation of the extravascular coagulation system. For example, it seems reasonable to have a mechanism that regulates the generated thrombin to prevent the formation of excess amounts of fibrin deposits. Dissolution of the extravascular fibrin deposits requires plasmin, which may be formed by action of the macrophage uPA, provided that plasminogen is available. Plasminogen may be available due to extravasation of plasma components during the inflammatory response, but it should also be noted that plasminogen can be found normally at extravascular locations (48) . This study shows that MC chymase may potentially also be involved in regulation of plasmin levels by degrading it in a heparin-dependent manner. Possibly, this system could provide a means for degrading plasmin after it has fulfilled its role in fibrin degradation and thus prevent the accumulation of excess amounts of plasmin in the tissue. Our results show that plasmin inactivation was close to undetectable after inactivation of the NDST-2 gene, indicating that the MC chymase:heparin PG system provides the main mechanism for control of formed plasmin in this cellular system. Regulation of the plasmin/plasminogen activator system by MC chymase could be relevant in relation to several pathophysiological conditions. It is well established that plasminogen activator/plasmin plays a central role in tumor metastasis by supporting cancer cell invasion through the extracellular matrix (49) . For example, experiments with uPA -/-(50, 51) and plasminogen -/-(52, 53) mice have provided strong evidence for uPA-catalyzed plasmin generation as a rate-limiting factor for tumor growth and metastases formation. Further, plasminogen activator/plasmin has been shown to be of central importance in wound healing (54) . Given the present results, we may speculate that MCs, by exposing chymase-heparin PG complexes may have the capacity to modulate processes where the plasmin/plasminogen activator system is involved. In this context, it should be noted that MCs show a strong tendency to accumulate at sites of ongoing tumor metastasis (2) and wound healing (3) . At these sites, the MCs are typically located in the normal tissue, in close proximity to the affected tissue (2).
The results presented here support a critical role for the heparin moiety of the chymase-heparin PG complex for optimal rates of substrate proteolysis. This finding agrees with several previous reports where heparin has been shown to accelerate chymase-catalyzed cleavage of various substrates (14, 15, 30, 55, 56) . A recent investigation of the mechanism by which heparin influences chymase function resulted in a model where the heparin chains bind simultaneously to both chymase and substrate, thus bridging them and presenting the substrate to the active site of the chymases (14) . According to this model, heparin would direct the selection of potential substrates based on their heparin-binding properties; that is, heparin-binding substrates would be the preferred substrates, whereas proteins without heparin-binding properties should be deselected. The heparin PG would thus act as a "coreceptor" in an analogous fashion as cell surface heparan sulfate PGs are thought to function as coreceptors in the binding of certain growth factors to their respective receptors (57, 58) . The present findings support such a role for heparin in chymase-catalyzed degradation of both thrombin and plasmin. First, both thrombin (59) and plasmin (60) are heparin-binding proteins, whereas Factor Xa, which was not inactivated by chymase-heparin PG, does not interact with heparin. Second, blocking of heparin by adding a polycationic heparin antagonist caused virtually complete blocking of chymasecatalyzed inactivation of both thrombin and plasmin. The heparin antagonist caused only a relatively small reduction of chymase activity towards a chromogenic substrate, indicating that the actual active site of chymase was not affected to a major extent. Thus, the reduction of thrombin/plasmin inactivation in the presence of polycation would be explained by blocking of the free heparin portions in the chymase-heparin PG complexes (see Fig. 9 ). This finding would lead to an absence of free glycosaminoglycan for the target molecules to interact with, resulting in decreased rates of proteolysis.
We note that the chymase-heparin PG complexes are associated with the MC surface rather than being released into the surrounding medium. Further, we detect considerable cell surface chymase activity on nonactivated MCs, indicating that chymase-heparin complexes may be presented by MCs in normal tissue and not just following MC degranulation. This finding agrees with earlier observations where cell surface chymase-heparin PG complexes were found on the surface of resting rat MCs (35) . The major part of the chymase-heparin PG complexes appeared to be cell surface-bound also after in vitro activation of the cells. Thus, the newly exocytosed chymase-heparin PG complexes would tend to re-associate with the MC surface and hence be prevented from escaping into the surrounding tissue. The in vivo significance of this finding remains to be demonstrated. However, it is possible that such a mechanism serves to localize the powerful chymase molecules at the site of MC degranulation. Extensive diffusion of these enzymes to sites distant from their intended site of action may indeed be harmful for the organism.
Peritoneal mast cells are known to express at least two different chymases, mMCP-4 and mMCP -5. Because both mMCP-4 and -5 are highly basic and thus capable of interaction with heparin, either or both of these chymases may be responsible for the observed degradation of thrombin and plasmin. However, because no reagents that specifically block either mMCP-4 or -5 activity are available, we cannot at present distinguish whether these proteases are degraded primarily by mMCP-4 or mMCP-5. mMCP-4 belongs to the β-subfamily of chymases, whereas mMCP-5 is classified as an α-chymase. We thus cannot determine whether thrombin and plasmin inactivation is a particular feature of either β-or α-chymases, or whether both classes of chymases recognize these enzymes as substrates. This determination may be relevant when extending the present observations to human mast cells, which show expression of only one α-chymase.
In conclusion, our results support a model for the regulation of extravascular coagulation and fibrinolysis where macrophages and MCs are the main players (Fig. 9) . Macrophages display potent prothrombinase activity as well as uPA. Following the exposure of macrophages to prothrombin or plasminogen, these zymogens will be processed into their active forms, thrombin and plasmin. Once formed, they may carry out their designed functions in connection with the particular prevalent condition. Our results indicate that MCs may provide the main mechanism for the subsequent inactivation of these proteases at extravascular sites. The mechanism involves binding of thrombin and plasmin, through their respective heparin-binding regions, to the heparin moiety of the MC chymase:heparin PG complex on the MC surface. This interaction will allow presentation of thrombin and plasmin to the MC chymase, thus accelerating their chymasecatalyzed degradation. Moreover, we speculate that this mechanism will be functional not only for thrombin and plasmin, but also for a variety of heparin-binding substrates; for example, fibronectin (56) . Hence, the association of chymase with heparin PG will serve both to select preferentially heparin-binding substrates as well as to increase the rate of proteolysis. +/+ and NDST-2 -/-mice were cultured overnight, followed by the addition of 2 µg plasminogen/well. Media samples (300 µl) were collected at the time points indicated and were subjected to Western blot analysis by using an antiplasminogen antiserum. As a control, plasminogen was incubated in cell culture medium without cells for 5 h. +/+ mice were cultured ~20 h. A) Plasminogen activator inhibitor 1 (PAI-1; □; 9 µg/well), anti-uPA antibodies (20 µg/well; ∆) or control antibody (20 µg/well; ◊) were added to cell cultures and, after an additional 30 min of incubation, plasminogen (2 µg/well) was added. Plasminogen-activating activity was also monitored in the absence of inhibitors (■). B) Cells were incubated for 30 min with amiloride at 0.01 mM (□), 0.1 mM (∆), or 1 mM (◊), followed by the addition of plasminogen (2 µg/well). Plasminogen activator activity was also monitored in the absence of amiloride (n) . Samples from the culture media were collected at the time points indicated and were analyzed for plasmin-like activity with S-2403. Results are expressed as the mean of duplicate determinations ± range of variation within a single experiment. Error bars are frequently smaller than the size of the symbols. +/+ mice were cultured ~20 h. Calcium ionophore A23187 (0.5 µM; ○) or anti-mouse IgE (2 µg/well; ∆) were added to cell cultures and, after an additional 30 min of incubation, plasmin (2 µg/well) was added. Plasmin-inactivating activity was also monitored in the absence of MC activators (•). Media samples (50 µl) were collected at the time points indicated and were analyzed for plasmin-like activity with the chromogenic substrate S-2403. Results are expressed as the mean of duplicate determinations ± range of variation within a single experiment. Error bars are frequently smaller than the size of the symbols. (Factors Xa and Va) and uPA bound to its cellular receptor, uPAR. Exposure of macrophages to prothrombin and plasminogen will result in the formation of thrombin and plasmin, respectively. MCs express and expose chymase:heparin PG complexes on their cell surface. Binding of thrombin and plasmin, mediated by their heparin-binding regions (+++), to the heparin moiety of the chymase:heparin PG complex will facilitate contact between chymase and potential macromolecular substrates, and thus accelerate the rate of chymase-catalyzed proteolysis of both thrombin and plasmin.
